Spots Global Cancer Trial Database for leukemia, chronic lymphocytic
Every month we try and update this database with for leukemia, chronic lymphocytic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | NCT02973399 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | NCT02973399 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL | NCT02914327 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) | NCT05947851 | Leukemia, Lymph... Leukemia, Chron... Small-Cell Lymp... Lymphoma, Small... CLL SLL | Nemtabrutinib Venetoclax Rituximab | 18 Years - | Merck Sharp & Dohme LLC |